Novartis International AG: Novartis secures exclusive rights for potential acute respiratory distress syndrome cell therapy
Novartis enters into exclusive worldwide license with Mesoblast to develop, commercialize and manufacture remestemcel-L for treatment of acute respiratory distress syndrome (ARDS) and other indicat… FinanzNachrichten.de: Meistgelesene Nachrichten
